BioSyent Inc.
TSX VENTURE : RX

BioSyent Inc.

June 04, 2013 08:00 ET

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 Year Revenue Growth Rate of 355%

TORONTO, ONTARIO--(Marketwired - June 4, 2013) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that PROFIT Magazine has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2013 rankings. Published in the Summer issue of PROFIT Magazine and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2007-2012) growth rate of 355%, BioSyent ranked #183 on the PROFIT 500 list.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

About PROFIT Magazine and PROFITguide.com

PROFIT: Your Guide to Business Success is Canada's preeminent publication dedicated to the management issues and opportunities facing small and mid-sized businesses. For 31 years, Canadian entrepreneurs and senior managers across a vast array of economic sectors have remained loyal to PROFIT because it's a timely and reliable source of actionable information that helps them achieve business success and get the recognition they deserve for generating positive economic and social change. Visit PROFIT online at PROFITguide.com.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contact Information